ArticleMedicine2026
Treatment of elderly patients with advanced (M1) gallbladder cancer - Aggressive or conservative?: A retrospective cohort study based on the SEER database.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The optimal treatment strategy for elderly patients with distant metastatic gallbladder cancer (GBC, M1) remains controversial. We extracted data from the Surveillance, Epidemiology, and End Results (SEER) database for 528 elderly patients (aged ≥ 60 years) diagnosed with M1 GBC between 2000 and 2020. Patients were stratified by age (60-69, 70-79, ≥80 years) and treatment received: no surgery or chemotherapy (Group N), surgery alone (Group S), chemotherapy alone (Group C), or surgery combined with chemotherapy (Group B). Kaplan-Meier analysis, multivariate logistic regression, and Cox proportional hazards models were used to identify prognostic factors. In the 60-69 age group, Group B had the longest mean survival (8.94 ± 6.71 months) and the best survival curve. In the 70-79 group, all active treatments were protective, with Group B showing the strongest benefit (HR = 0.16, 95% CI 0.07-0.39, P < .001) and a mean survival of 9.92 ± 5.46 months. In the ≥ 80 group, Group B also yielded the longest mean survival (10.54 ± 9.68 months) with significantly better survival curves. Surgery combined with chemotherapy appears to improve prognosis in elderly M1 GBC patients, particularly in those aged 70-79 years, and should be considered a protective factor. However, the retrospective nature, lack of performance status and detailed treatment data, and small subgroup sizes warrant caution in interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.